Literature DB >> 25796092

Gross tumor volume and clinical target volume in prostate cancer: How do satellites relate to the index lesion.

Birgit G Hollmann1, Baukelien van Triest1, Ghazaleh Ghobadi1, Greetje Groenendaal1, Jeroen de Jong2, Henk G van der Poel3, Uulke A van der Heide1.   

Abstract

PURPOSE: There is an increasing interest for dose differentiation in prostate radiotherapy. The purpose of our study was to analyze the spatial distribution of tumor satellites inside the prostate. METHODS AND MATERIALS: 61 prostatectomy specimens were stained with H&E. Tumor regions were delineated by the uro-pathologist. Volumes, distances and cell densities of all delineated tumor regions were measured and further analyzed.
RESULTS: Multifocal disease was seen in 84% of the patients. The median number of tumor foci was 3. The median distance between the index lesion and the satellites was 1.0 cm, with a maximum of 4.4 cm. The index lesions accounted for 88% of the total tumor volume. The contribution of tumor foci<0.1 cm(3) to the total tumor volume was 2%. The median cell density of the index lesion and all satellites, regardless of size, were significantly higher than that of the prostate.
CONCLUSIONS: Satellites do not appear in a limited margin around the index lesion (GTV). Consequently, a fixed CTV margin would not effectively cover all satellites. Thus if the aim is to treat all tumor foci, the entire prostate gland should be considered CTV.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Index lesion; Pathology; Prostate cancer; Radiotherapy; Satellites; Spatial distribution

Mesh:

Year:  2015        PMID: 25796092     DOI: 10.1016/j.radonc.2015.01.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

1.  Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy.

Authors:  J V Hegde; D J Margolis; P-C Wang; R E Reiter; J Huang; M L Steinberg; M Kamrava
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-01-31       Impact factor: 5.554

2.  Post-therapy pathologic tumor volume predicts survival in gastric cancer patients who underwent neoadjuvant chemotherapy and gastrectomy.

Authors:  Xiaolong Tang; Qingsi He; Hui Qu; Guorui Sun; Jia Liu; Lei Gao; Jingbo Shi; Jianhong Ye; Yahang Liang
Journal:  BMC Cancer       Date:  2019-08-13       Impact factor: 4.430

3.  4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study.

Authors:  Lucian Beer; Stephan H Polanec; Pascal A T Baltzer; Georg Schatzl; Dietmar Georg; Christian Schestak; Anja Dutschke; Harald Herrmann; Peter Mazal; Alexander K Brendel; Shahrokh F Shariat; Helmut Ringl; Thomas H Helbich; Paul Apfaltrer
Journal:  PLoS One       Date:  2019-12-19       Impact factor: 3.240

4.  Phase I study of dose escalation to dominant intraprostatic lesions using high-dose-rate brachytherapy.

Authors:  Christopher H Chapman; Steve E Braunstein; Jean Pouliot; Susan M Noworolski; Vivian Weinberg; Adam Cunha; John Kurhanewicz; Alexander R Gottschalk; Mack Iii Roach; I-Chow Hsu
Journal:  J Contemp Brachytherapy       Date:  2018-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.